Drug intelligence / Profile preview

guanfacine

Development stage: Approved
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

Guanfacine is a selective alpha-2A adrenergic receptor agonist used primarily to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents, as well as hypertension. It works by activating alpha-2A-adrenoceptors within the central nervous system, leading to reduced sympathetic outflow and lower blood pressure. In ADHD, guanfacine is believed to enhance prefrontal cortex function by stimulating post-synaptic alpha-2A-adrenoceptors on dendritic spines, which improves attention regulation and behavioral inhibition. The drug was first described in 1974 and received FDA approval in 1986[1][3][4][6].

Brand names: IntunivTenex
Other names: guanfacine

Targets

HTR2B (5-Hydroxytryptamine Receptor 2B)ADRA2A (α2A)

Beyond the preview

Go deeper on guanfacine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on guanfacine.

Explore the full profile